Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Advances in Respiratory Medicine
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Author statement Editorial Policy and Information for Authors

open access

Vol 85, No 6 (2017)
ORIGINAL PAPERS
Published online: 2017-12-18
Submitted: 2017-10-23
Accepted: 2017-12-14
View PDF Download PDF file
Get Citation

The utility of selected questionnaires in the assessment of fatigue, depression and health quality in post-sarcoidosis fatigue syndrome

Witold Górski, Łukasz Mokros, Anna Kumor-Kisielewska, Tadeusz Pietras, Wojciech J. Piotrowski
DOI: 10.5603/ARM.2017.0054
·
Pubmed: 29288480
·
Adv Respir Med 2017;85(6):313-321.

open access

Vol 85, No 6 (2017)
ORIGINAL PAPERS
Published online: 2017-12-18
Submitted: 2017-10-23
Accepted: 2017-12-14

Abstract

Introduction: The nature of post-sarcoidosis fatigue syndrome (PSFS) is unknown and tools for the assessment of health quality (HQ) in these patients have not been fully assessed. The aim was to validate the Polish version of sarcoidosis health questionnaire (SHQ) and verify the association of HQ with fatigue and depressive symptoms among Polish patients with PSFS. Material and methods: 71 patients with sarcoidosis (34 women, the mean age 47) were divided to: PSFS (n = 21), active sarcoidosis (S-A, n = 27) and sarcoidosis with complete remission (S-R, n = 23) groups. Fatigue Assessment Scale (FAS) was used to define significant fatigue (≥ 22 points). Polish version of SHQ was prepared by the authors and validated. Beck Depression Index (BDI) and Patient Health Questionnaire 9 (PHQ-9) were used to evaluate self-reported depressive symptoms. Results: Polish version of SHQ was proved reliable and valid. HQ was worse and depressive symptoms were more frequent in PSFS and S-A when compared with S-R group. SHQ total score correlated negatively with depressive symptoms (r = -0.787 for BDI and r = -0,755 for PHQ-9, p < 0.01). A negative correlation between SHQ and FAS score was found (r = –0.784, p < 0.01). FAS score correlated with depressive symptoms (r = 0.726 for BDI and r = 0.755 for PHQ-9, p < 0.01). Conclusion: Polish version of SHQ is a valuable tool for the assessment of HQ in sarcoidosis. HQ is impaired in PSFS comparing to patients with complete remission, but is comparable to active sarcoidosis. Depressive symptoms impact HQ and may influence perception of fatigue. Both fatigue and depression have a negative impact on HQ in sarcoidosis.

Abstract

Introduction: The nature of post-sarcoidosis fatigue syndrome (PSFS) is unknown and tools for the assessment of health quality (HQ) in these patients have not been fully assessed. The aim was to validate the Polish version of sarcoidosis health questionnaire (SHQ) and verify the association of HQ with fatigue and depressive symptoms among Polish patients with PSFS. Material and methods: 71 patients with sarcoidosis (34 women, the mean age 47) were divided to: PSFS (n = 21), active sarcoidosis (S-A, n = 27) and sarcoidosis with complete remission (S-R, n = 23) groups. Fatigue Assessment Scale (FAS) was used to define significant fatigue (≥ 22 points). Polish version of SHQ was prepared by the authors and validated. Beck Depression Index (BDI) and Patient Health Questionnaire 9 (PHQ-9) were used to evaluate self-reported depressive symptoms. Results: Polish version of SHQ was proved reliable and valid. HQ was worse and depressive symptoms were more frequent in PSFS and S-A when compared with S-R group. SHQ total score correlated negatively with depressive symptoms (r = -0.787 for BDI and r = -0,755 for PHQ-9, p < 0.01). A negative correlation between SHQ and FAS score was found (r = –0.784, p < 0.01). FAS score correlated with depressive symptoms (r = 0.726 for BDI and r = 0.755 for PHQ-9, p < 0.01). Conclusion: Polish version of SHQ is a valuable tool for the assessment of HQ in sarcoidosis. HQ is impaired in PSFS comparing to patients with complete remission, but is comparable to active sarcoidosis. Depressive symptoms impact HQ and may influence perception of fatigue. Both fatigue and depression have a negative impact on HQ in sarcoidosis.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

post-sarcoidosis fatigue syndrome, sarcoidosis, health quality, fatigue, FAS

About this article
Title

The utility of selected questionnaires in the assessment of fatigue, depression and health quality in post-sarcoidosis fatigue syndrome

Journal

Advances in Respiratory Medicine

Issue

Vol 85, No 6 (2017)

Pages

313-321

Published online

2017-12-18

DOI

10.5603/ARM.2017.0054

Pubmed

29288480

Bibliographic record

Adv Respir Med 2017;85(6):313-321.

Keywords

post-sarcoidosis fatigue syndrome
sarcoidosis
health quality
fatigue
FAS

Authors

Witold Górski
Łukasz Mokros
Anna Kumor-Kisielewska
Tadeusz Pietras
Wojciech J. Piotrowski

References (37)
  1. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011; 183(5): 573–581.
    CrossRefPubMed
  2. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007; 357(21): 2153–2165.
    CrossRefPubMed
  3. Wirnsberger RM, de Vries J, Wouters EF, et al. Clinical presentation of sarcoidosis in The Netherlands an epidemiological study. Neth J Med. 1998; 53(2): 53–60.
    PubMed
  4. Michielsen HJ, Drent M, Peros-Golubicic T, et al. Fatigue is associated with quality of life in sarcoidosis patients. Chest. 2006; 130(4): 989–994.
    CrossRefPubMed
  5. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest. 2008; 133(5): 1189–1195.
    CrossRefPubMed
  6. Lower EE, Malhotra A, Surdulescu V, et al. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage. 2013; 45(2): 159–169.
    CrossRefPubMed
  7. Centers for Disease Control and Prevention. http://www.cdc. gov/cfs/case-definition (28.01.2016).
  8. Whitehead L. The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. J Pain Symptom Manage. 2009; 37(1): 107–128.
    CrossRefPubMed
  9. Sharma OmP. Fatigue and sarcoidosis. Eur Respir J . 1999; 13: 713–714.
  10. Górski W, Piotrowski WJ. Fatigue syndrome in sarcoidosis. Pneumonol Alergol Pol. 2016; 84(4): 244–250.
    CrossRefPubMed
  11. Korenromp IHE, Heijnen CJ, Vogels OJM, et al. Characterization of chronic fatigue in patients with sarcoidosis in clinical remission. Chest. 2011; 140(2): 441–447.
    CrossRefPubMed
  12. Korenromp IHE, Grutters JC, van den Bosch JMM, et al. Post-inflammatory fatigue in sarcoidosis: personality profiles, psychological symptoms and stress hormones. J Psychosom Res. 2012; 72(2): 97–102.
    CrossRefPubMed
  13. Chang B, Steimel J, Moller DR, et al. Depression in sarcoidosis. Am J Respir Crit Care Med. 2001; 163(2): 329–334.
    CrossRefPubMed
  14. Holas P, Krejtz I, Urbankowski T, et al. Anxiety, its relation to symptoms severity and anxiety sensitivity in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013; 30(4): 282–288.
    PubMed
  15. Goracci A, Fagiolini A, Martinucci M, et al. Quality of life, anxiety and depression in sarcoidosis. Gen Hosp Psychiatry. 2008; 30(5): 441–445.
    CrossRefPubMed
  16. de Kleijn WPE, Drent M, De Vries J. Nature of fatigue moderates depressive symptoms and anxiety in sarcoidosis. Br J Health Psychol. 2013; 18(2): 439–452.
    CrossRefPubMed
  17. De Vries J, Michielsen H, Van Heck GL, et al. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol. 2004; 9(Pt 3): 279–291.
    CrossRefPubMed
  18. Cox CE, Donohue JF, Brown CD, et al. The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life. Am J Respir Crit Care Med. 2003; 168(3): 323–329.
    CrossRefPubMed
  19. American Thoracic Society, European Respiratory Society, World Association of Sarcoidosis and Other Granulomatous Disorders: Statement on sarcoidosis. Am J Respir Crit Care Med. 1999; 160(2): 736–755.
    CrossRefPubMed
  20. Polish Society of Respiratory Diseases. The recommendations of the Polish Society Pneumological on spirometry. Pneumonol Alergol Pol. 2006; 74(Suppl 1).
  21. Sterk PJ, Fabbri LM, Quanjer PH, et al. Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir J Suppl. 1993; 16: 1–100.
    PubMed
  22. Anastasi A, Urbina S. Psychological testing. Prentice 1997.
  23. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4: 561–571.
    PubMed
  24. Beck A, Steer RA, Brown G. Beck Depression Inventory–II. PsycTESTS Dataset. 2011.
    CrossRef
  25. Zawadzki B, Popiel A, Pragłowska E. Psychometric properties of the Polish version of the Aaron T. Beck’s Depression Inventory BDI. Psychologia ― Etologia ― Genetyka. 2009; 19: 71–95.
  26. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16(9): 606–613.
    PubMed
  27. http://www.phqscreeners.com/sites/g/files/g10016261/f/201412/PHQ9_Polish%20for%20Poland.pdf. (12.10.2017).
  28. WASOG World Association for Sarcoidosis and Other Granulomatous Disorders. http://www.wasog.org/education-research/questionnaires.html (12.10.2017).
  29. http://vassarstats.net/rdiff.html (12.0.2017).
  30. Tavakol M, Dennick R. Making sense of Cronbach's alpha. Int J Med Educ. 2011; 2: 53–55.
    CrossRefPubMed
  31. Tanizawa K, Handa T, Nagai S, et al. Validation of the Japanese version of the Sarcoidosis Health Questionnaire: a cross-sectional study. Health Qual Life Outcomes. 2011; 9: 34.
    CrossRefPubMed
  32. Lomper K, Chudiak A, Uchmanowicz I, et al. Effects of depression and anxiety on asthma-related quality of life. Pneumonol Alergol Pol. 2016; 84(4): 212–221.
    CrossRefPubMed
  33. Nguyen C, Ranque B, Baubet T, et al. Groupe Français de Recherche sur la Sclérodermie. Clinical, functional and health-related quality of life correlates of clinically significant symptoms of anxiety and depression in patients with systemic sclerosis: a cross-sectional survey. PLoS One. 2014; 9(2): e90484.
    CrossRefPubMed
  34. Sivertsen H, Bjørkløf GH, Engedal K, et al. Depression and Quality of Life in Older Persons: A Review. Dement Geriatr Cogn Disord. 2015; 40(5-6): 311–339.
    CrossRefPubMed
  35. Baydur A, Alavy B, Nawathe A, et al. Fatigue and plasma cytokine concentrations at rest and during exercise in patients with sarcoidosis. Clin Respir J. 2011; 5(3): 156–164.
    CrossRefPubMed
  36. Zieleźnik K, Jastrzębski D, Ziora D. Fatigue in patients with inactive sarcoidosis does not correlate with lung ventilation ability or walking distance. Pilot Study. Pneumonol Alergol Pol. 2015; 83(1): 14–22.
    CrossRefPubMed
  37. de Kleijn WPE, De Vries J, Wijnen PA, et al. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med. 2011; 105(9): 1388–1395.
    CrossRefPubMed

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl